Stocksigma LogoStocksigma Logo

Senores Pharmaceuticals Reports Strong Q2 and H1 FY27 Performance

Senores Pharmaceuticals posted its highest-ever quarterly revenue and EBITDA in Q2FY27, with revenue growing 24.9% YoY to ₹192.3 crore, EBITDA rising 38%

Senores Pharmaceuticals Reports Strong Q2 and H1 FY27 Performance

Senores Pharmaceuticals Ltd · Press Release · 29 Oct 2026, 7:35 pm

Senores Pharmaceuticals Reports Strong Q2 and H1 FY27 Performance Senores Pharmaceuticals posted its highest-ever quarterly revenue and EBITDA in Q2FY27, with revenue growing 24.9% YoY to ₹192.3 crore, EBITDA rising 38% YoY to ₹58 crore, and PAT increasing 22% YoY to ₹37 crore. For H1FY27, revenue reached ₹372.5 crore (+30% YoY), while PAT rose 31% YoY to ₹67 crore. Regulated markets drove growth, surging 34.3% YoY in H1FY27 to ₹264.5 crore. Operating cash flow improved to ₹38 crore. Management reaffirmed FY27 guidance of 30–40% revenue growth and 50–60% PAT growth.

Original exchange filing (PDF)

More announcements from Senores Pharmaceuticals Ltd

All Senores Pharmaceuticals Ltd announcements